Suppression of Growth Hormone (Acromegaly)
Antidiarrheal (AIDS Patients)
Actions mimic those of the natural hormone somatostatin. Suppresses secretion of serotonin and gastroenteropancreatic peptides (eg, gastrin, insulin, glucagon, secretin, motilin). Also suppresses growth hormone.
Use Cautiously in:
CV: Sinus bradycardia (25%); hypertension (13%); conduction abnormalities (10%); arrhythmias (9%); arterial thrombosis of the arm; atrial fibrillation, cardiac arrest, orthostatic hypotension, retinal vein thrombosis (postmarketing).
CNS: Fatigue (32%); headache (30%); dizziness (20%); depression, weakness (1% to 4%); aphasia, Bell palsy, convulsions, decreased libido, intracranial hemorrhage, migraines, paranoia (postmarketing).
DERM: Pruritus (18%); rash (15%); alopecia (13%); bruise, flushing (1% to 4%); facial edema, petechiae, urticaria (postmarketing).
EENT: Blurred vision, visual disturbances (1% to 4%); deafness, glaucoma, scotoma, visual field defect (postmarketing).
GI: Diarrhea (58%); abdominal pain or discomfort (44%); nausea (41%); abdominal pain (35%); nausea (30%); flatulence (26%); constipation (19%); vomiting (16%); appendicitis, gallbladder polyp, GI hemorrhage, intestinal obstruction; pancreatitis, peptic/gastric ulcer (postmarketing).
GU: Pollakiuria, UTI (1% to 4%); breast carcinoma, gynecomastia, hematuria, renal failure, renal insufficiency (postmarketing).
HEMA/LYMPH: Anemia (15%); pancytopenia, thrombocytopenia (postmarketing).
HEPA: Cholelithiasis (38%); decreased liver enzymes, fatty liver, hepatitis (postmarketing).
HYPERSEN: Octreotide antibodies (25%); anaphylactic shock (postmarketing).
LABTESTABS: Increased creatine kinase, increased creatinine (postmarketing)
LOCAL: Injection-site pain (30% to 50%); injection-site hematoma (1% to 4%).
M/N: Hyperglycemia (27%); hypothyroidism (12%); hypoglycemia (4%); fat metabolism (1% to 4%); diabetes insipidus, diabetes mellitus, galactorrhea (postmarketing).
MUSC: Back pain (27%); arthropathy (19%); myalgia (18%); musculoskeletal pain (15%); joint pain (1% to 4%); arthritis, joint effusion (postmarketing).
RESP: Upper respiratory tract infection (23%); sinusitis (15%); aggravated pneumothorax, pulmonary hypertension, pulmonary nodule, status asthmaticus (postmarketing).
OTHER: Influenza-like symptoms (20%); generalized pain (15%); upper abdominal pain (11%); goiter (8%); cold symptoms, edema (1% to 4%); aneurysm, enlarged abdomen, hemiparesis, paresis, pituitary apoplexy, Raynaud syndrome, suicide attempt (postmarketing).
Beta-blockers and other bradycardia-inducing drugs
Octreotide has additive effect on heart rate reduction.
Availability may be increased by octreotide.
May decrease plasma levels of cyclosporine.
Hypoglycemic agents, insulin
Insulin and glucagon secretion may be inhibited by octreotide; monitor blood glucose when starting, stopping or changing the dose of octreotide and adjust antidiabetic treatment as needed.
Parenteral nutrition solutions.
Therapeutic Classification: antidiarrheals, hormones
Absorption: Well absorbed following subcut administration and IM administration of depot form.
Protein Binding: 65%.
Metabolism/Excretion: 32% excreted unchanged in urine.
Half-life: 1.5 hr.
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal